Shares of Enliven Therapeutics (ELVN) are up nearly 20% to $37.22 in pre-market trading after rival drug developer Terns Pharmaceuticals (TERN) announced an agreement to be acquired by pharma giant Merck (MRK) for $53.00 per share in cash for an approximate equity value of $6.7B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN: